These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
227 related articles for article (PubMed ID: 28293802)
1. History of hypertension, heart disease, and diabetes and ovarian cancer patient survival: evidence from the ovarian cancer association consortium. Minlikeeva AN; Freudenheim JL; Cannioto RA; Szender JB; Eng KH; Modugno F; Ness RB; LaMonte MJ; Friel G; Segal BH; Odunsi K; Mayor P; Zsiros E; Schmalfeldt B; Klapdor R; Dӧrk T; Hillemanns P; Kelemen LE; Kӧbel M; Steed H; de Fazio A; ; Jordan SJ; Nagle CM; Risch HA; Rossing MA; Doherty JA; Goodman MT; Edwards R; Matsuo K; Mizuno M; Karlan BY; Kjær SK; Høgdall E; Jensen A; Schildkraut JM; Terry KL; Cramer DW; Bandera EV; Paddock LE; Kiemeney LA; Massuger LF; Kupryjanczyk J; Berchuck A; Chang-Claude J; Diergaarde B; Webb PM; Moysich KB; Cancer Causes Control; 2017 May; 28(5):469-486. PubMed ID: 28293802 [TBL] [Abstract][Full Text] [Related]
2. Antihypertensive medication use and ovarian cancer survival. Huang T; Townsend MK; Dood RL; Sood AK; Tworoger SS Gynecol Oncol; 2021 Nov; 163(2):342-347. PubMed ID: 34556331 [TBL] [Abstract][Full Text] [Related]
3. Hypertension, use of antihypertensive medications, and risk of epithelial ovarian cancer. Huang T; Poole EM; Eliassen AH; Okereke OI; Kubzansky LD; Sood AK; Forman JP; Tworoger SS Int J Cancer; 2016 Jul; 139(2):291-9. PubMed ID: 26934358 [TBL] [Abstract][Full Text] [Related]
4. Post-diagnosis use of antihypertensive medications and the risk of death from ovarian cancer. Harding BN; Delaney JA; Urban RR; Weiss NS Gynecol Oncol; 2019 Aug; 154(2):426-431. PubMed ID: 31178150 [TBL] [Abstract][Full Text] [Related]
5. History of Comorbidities and Survival of Ovarian Cancer Patients, Results from the Ovarian Cancer Association Consortium. Minlikeeva AN; Freudenheim JL; Eng KH; Cannioto RA; Friel G; Szender JB; Segal B; Odunsi K; Mayor P; Diergaarde B; Zsiros E; Kelemen LE; Köbel M; Steed H; deFazio A; Jordan SJ; Fasching PA; Beckmann MW; Risch HA; Rossing MA; Doherty JA; Chang-Claude J; Goodman MT; Dörk T; Edwards R; Modugno F; Ness RB; Matsuo K; Mizuno M; Karlan BY; Goode EL; Kjær SK; Høgdall E; Schildkraut JM; Terry KL; Cramer DW; Bandera EV; Paddock LE; Kiemeney LA; Massuger LFAG; Sutphen R; Anton-Culver H; Ziogas A; Menon U; Gayther SA; Ramus SJ; Gentry-Maharaj A; Pearce CL; Wu AH; Kupryjanczyk J; Jensen A; Webb PM; Moysich KB; ; Cancer Epidemiol Biomarkers Prev; 2017 Sep; 26(9):1470-1473. PubMed ID: 28864456 [No Abstract] [Full Text] [Related]
6. The impact of perioperative β blocker use on patient outcomes after primary cytoreductive surgery in high-grade epithelial ovarian carcinoma. Al-Niaimi A; Dickson EL; Albertin C; Karnowski J; Niemi C; Spencer R; Shahzad MM; Uppal S; Saha S; Rice L; Nally AM Gynecol Oncol; 2016 Dec; 143(3):521-525. PubMed ID: 27693123 [TBL] [Abstract][Full Text] [Related]
7. Joint exposure to smoking, excessive weight, and physical inactivity and survival of ovarian cancer patients, evidence from the Ovarian Cancer Association Consortium. Minlikeeva AN; Cannioto R; Jensen A; Kjaer SK; Jordan SJ; Diergaarde B; Szender JB; Odunsi K; Almohanna H; Mayor P; Starbuck K; Zsiros E; Bandera EV; Cramer DW; Doherty JA; DeFazio A; ; Edwards R; Goode EL; Goodman MT; Høgdall E; Matsuo K; Mizuno M; Nagle CM; Ness RB; Paddock LE; Pearce CL; Risch HA; Rossing MA; Terry KL; Wu AH; Modugno F; Webb PM; Moysich KB; Cancer Causes Control; 2019 May; 30(5):537-547. PubMed ID: 30905014 [TBL] [Abstract][Full Text] [Related]
8. Impact of beta blockers on survival outcomes in ovarian cancer: a nationwide population-based cohort study. Baek MH; Kim DY; Kim SO; Kim YJ; Park YH J Gynecol Oncol; 2018 Nov; 29(6):e82. PubMed ID: 30207092 [TBL] [Abstract][Full Text] [Related]
9. Beta-blocker use and mortality following ovarian cancer diagnosis: a population-based study. Couttenier A; Lacroix O; Silversmit G; Vaes E; De Schutter H; Robert A Cancer Epidemiol; 2019 Oct; 62():101579. PubMed ID: 31450179 [TBL] [Abstract][Full Text] [Related]
10. Prognosis of ovarian cancer in women with type 2 diabetes using metformin and other forms of antidiabetic medication or statins: a retrospective cohort study. Urpilainen E; Marttila M; Hautakoski A; Arffman M; Sund R; Ilanne-Parikka P; Arima R; Kangaskokko J; Puistola U; Hinkula M; Läärä E BMC Cancer; 2018 Jul; 18(1):767. PubMed ID: 30055585 [TBL] [Abstract][Full Text] [Related]
11. Impact of diabetes mellitus on epithelial ovarian cancer survival. Akhavan S; Ghahghaei-Nezamabadi A; Modaresgilani M; Mousavi AS; Sepidarkish M; Tehranian A; Rezayof E BMC Cancer; 2018 Dec; 18(1):1246. PubMed ID: 30541490 [TBL] [Abstract][Full Text] [Related]
12. Epidemiologic factors that predict long-term survival following a diagnosis of epithelial ovarian cancer. Kim SJ; Rosen B; Fan I; Ivanova A; McLaughlin JR; Risch H; Narod SA; Kotsopoulos J Br J Cancer; 2017 Mar; 116(7):964-971. PubMed ID: 28208158 [TBL] [Abstract][Full Text] [Related]
13. The effect of metabolic comorbidities and commonly used drugs on the prognosis of patients with ovarian cancer. Bar D; Lavie O; Stein N; Feferkorn I; Shai A Eur J Obstet Gynecol Reprod Biol; 2016 Dec; 207():227-231. PubMed ID: 27890326 [TBL] [Abstract][Full Text] [Related]
14. History of thyroid disease and survival of ovarian cancer patients: results from the Ovarian Cancer Association Consortium, a brief report. Minlikeeva AN; Freudenheim JL; Cannioto RA; Eng KH; Szender JB; Mayor P; Etter JL; Cramer DW; Diergaarde B; Doherty JA; Dörk T; Edwards R; deFazio A; Friel G; Goodman MT; Hillemanns P; Høgdall E; Jensen A; Jordan SJ; Karlan BY; Kjær SK; Klapdor R; Matsuo K; Mizuno M; Nagle CM; Odunsi K; Paddock L; Rossing MA; Schildkraut JM; Schmalfeldt B; Segal BH; Starbuck K; Terry KL; Webb PM; Zsiros E; Ness RB; Modugno F; Bandera EV; Chang-Claude J; Moysich KB Br J Cancer; 2017 Sep; 117(7):1063-1069. PubMed ID: 28817835 [TBL] [Abstract][Full Text] [Related]
15. Comparative safety of diabetes medications and risk of incident invasive breast cancer: a population-based cohort study. Calip GS; Yu O; Elmore JG; Boudreau DM Cancer Causes Control; 2016 May; 27(5):709-20. PubMed ID: 27053250 [TBL] [Abstract][Full Text] [Related]
16. Use of ß-blockers and mortality following ovarian cancer diagnosis: a population-based cohort study. Johannesdottir SA; Schmidt M; Phillips G; Glaser R; Yang EV; Blumenfeld M; Lemeshow S BMC Cancer; 2013 Feb; 13():85. PubMed ID: 23433478 [TBL] [Abstract][Full Text] [Related]
17. Survival in Advanced Epithelial Ovarian Cancer Associated with Cardiovascular Comorbidities and Type 2 Diabetes Mellitus. Slavchev S; Kornovski Y; Yordanov A; Ivanova Y; Kostov S; Slavcheva S Curr Oncol; 2021 Sep; 28(5):3668-3682. PubMed ID: 34590605 [TBL] [Abstract][Full Text] [Related]
18. Smoking may modify the association between neoadjuvant chemotherapy and survival from ovarian cancer. Kelemen LE; Warren GW; Koziak JM; Köbel M; Steed H Gynecol Oncol; 2016 Jan; 140(1):124-30. PubMed ID: 26549109 [TBL] [Abstract][Full Text] [Related]
19. Impact of long-term antihypertensive and antidiabetic medications on the prognosis of post-surgical colorectal cancer: the Fujian prospective investigation of cancer (FIESTA) study. Peng F; Hu D; Lin X; Liang B; Chen Y; Zhang H; Xia Y; Lin J; Zheng X; Niu W Aging (Albany NY); 2018 May; 10(5):1166-1181. PubMed ID: 29846174 [TBL] [Abstract][Full Text] [Related]
20. Impact of beta blockers on epithelial ovarian cancer survival. Diaz ES; Karlan BY; Li AJ Gynecol Oncol; 2012 Nov; 127(2):375-8. PubMed ID: 22819786 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]